Navigation Links
Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
Date:3/20/2009

BOSTON, March 20 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has signed an agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) to sell the Ovascope and Mastascope product line to Lifeline Biotechnologies for a combination of stock, assumption of debt and other consideration. Solos Endoscopy originally purchased the products from Lifeline Biotechnologies in 2007.

Lifeline Biotechnologies has agreed to assume a convertible debt from Solos, which will result in less dilution for its shareholders. In addition, the sale of the Ovascope and Mastascope will allow Solos to use its resources to support its expanding core business. Solos is currently in negotiations with Lifeline regarding distribution rights to these products once they are finally ready for the market. Solos will continue to focus its efforts in the area of women's healthcare by concentrating on its Mammoview product line, which is currently sold to hospitals nationwide.

"Although we feel that there is great potential in the Mastascope and Ovascope technology, due to the current state of the economy, our resources will be better utilized in strengthening our current product lines to an expanding customer base," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
2. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
3. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
4. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
5. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
6. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
7. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
8. Exelixis Sells 80% Stake in Artemis to Taconic
9. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
10. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
11. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... takes place February 5-6 at the University’s student center, Kehr Union, located ... as workshops and competitions for ample networking, learning and collaborating opportunities. , ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today provided an update on the ... District of Texas and announcing ... Inter Partes Re-examination ("IPR") proceedings that VTech and ... was initiated on only certain claims of two of ...
Breaking Biology Technology:
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
Breaking Biology News(10 mins):